MDGL
Madrigal Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
431.70
close · 2026-10-29
value
17
cheaper than peers17
quality
58
stronger fundamentals58
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 10.04× | 56 |
| forward P/E | 44.85× | 16 |
| price to book | 19.04× | 9 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 126.8% | 81 |
| operating margin | -29.8% | 67 |
| return on equity | -49.3% | 48 |
| debt to equity | 63.9% | 28 |
4 of 4 measures available
Facts
| market cap | $10B |
| free cash flow | -$156.4M |
| employees | 915 |
| first trade | 2007-02-06 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-07-30 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -12.85 | -21.90 | -19.99 | -17.23 |
| free cash flow | -$193.0M | -$462.0M | -$325.7M | -$225.1M |
| net income | -$288.3M | -$465.9M | -$373.6M | -$295.4M |
| revenue | $958.4M | $180.1M | $0 | $0 |
| unusual items | -$2.8M | $0 | $0 | not reported |